Zachary Roberts, M.D., Ph.D.
Board Member
Allogene Therapeutics, Inc. (ALLO)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Zachary Roberts, M.D., Ph.D.
Zachary Roberts, M.D., Ph.D. is recorded as CEO and Board Member at Allogene Therapeutics, Inc. (ALLO). Allogene Therapeutics, Inc. reported in an 8-K filed May 28, 2026 that Zachary Roberts, M.D., Ph.D. was appointed Class I director, effective July 1, 2026. Allogene Therapeutics, Inc. reported in an 8-K filed May 28, 2026 that Zachary Roberts, M.D., Ph.D. was appointed President and Chief Executive Officer, effective July 1, 2026.
“Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director, to serve until the Company's 2028 annual meeting of the stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.”
“On May 28, 2026, the Board of Directors (the "Board") of Allogene Therapeutics, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company's President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-07-01–present
-
Current
2026-07-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Allogene Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Geoffrey Parker CFO
- Tim Moore CTO
- Timothy Moore CTO
- Annie Yoshiyama Chief Accounting Officer
- Elizabeth Barrett Board Member
- Stephen Mayo, Ph.D. Board Member
- Vicki Sato, Ph.D. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.